Routine

GLP-1 receptor agonist & SGLT2 inhibitor therapy (type 2 diabetes)

GLP1/SGLT2 · Endocrine
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Guideline-preferred second-line agents in type 2 diabetes chosen for cardiovascular, renal and weight benefits independent of glucose lowering. Selection is driven by comorbidity rather than HbA1c alone.

Red flags

  • Euglycaemic diabetic ketoacidosis on SGLT2 inhibitor
  • Severe dehydration or acute kidney injury
  • Acute pancreatitis or gallbladder disease on GLP-1 agonist
  • Fournier gangrene (perineal necrotising infection)
  • Persistent severe vomiting (gastroparesis) on GLP-1 agonist

Assessment

Differential diagnosis

  • Suboptimal adherence/lifestyle
  • Type 1/LADA misclassification
  • Steroid-induced hyperglycaemia
  • Pancreatic diabetes

Investigations

  • HbA1c, weight/BMI and blood pressure
  • eGFR and urine ACR
  • Cardiovascular risk assessment and history of ASCVD/heart failure
  • Review of contraindications (pancreatitis, gastroparesis, recurrent DKA)

Management

  • After metformin, prioritise agent by dominant comorbidity
  • Choose SGLT2 inhibitor for heart failure or chronic kidney disease
  • Choose GLP-1 receptor agonist for established atherosclerotic disease or when weight loss is a priority
  • Counsel on injection vs oral route and gastrointestinal side effects for GLP-1 agonists
  • Warn about volume depletion, genital mycotic infection and euglycaemic DKA risk with SGLT2 inhibitors
  • Advise sick-day rules: withhold SGLT2 inhibitor during acute illness/dehydration/surgery
  • Reduce sulfonylurea/insulin to prevent hypoglycaemia when combining
  • Monitor HbA1c, weight, renal function and tolerability
  • Consider combining the two classes for additive cardiorenal and metabolic benefit

Drugs & doses

Semaglutide SC 0.25 mg weekly titrated to 1-2 mg, or oral 3-14 mg daily
Dulaglutide 0.75-4.5 mg SC weekly
Tirzepatide 2.5 mg SC weekly titrated to 15 mg (GIP/GLP-1)
Dapagliflozin 10 mg or empagliflozin 10-25 mg PO once daily

Disposition

Prescribe and monitor in primary care/diabetes clinic; refer complex cardiorenal patients for combined cardiology/nephrology input and stop agents promptly for red-flag events.

Complications & pitfalls

  • Euglycaemic DKA
  • Genital and urinary infections
  • Volume depletion/AKI
  • Gastrointestinal intolerance
  • Gallstones and pancreatitis (GLP-1)

Exam pearls

  • Choose by comorbidity, not just glucose: SGLT2 for heart failure/CKD, GLP-1 for ASCVD/weight
  • Stop SGLT2 inhibitors before major surgery and during significant illness to avoid euglycaemic DKA
  • Check ketones even with normal glucose in an unwell SGLT2-treated patient
  • Dual-incretin agents (tirzepatide) give the greatest HbA1c and weight reductions

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.